PCSK9 inhibitors for anti-inflammation in atherosclerosis: protocol for a systematic review and meta-analysis of randomised controlled trials
Introduction Atherosclerosis is the leading cause of cardiovascular disease (CVD), which is one of the most common causes of morbidity and mortality worldwide. Lipid accumulation and inflammation play a crucial role in the pathogenesis of atherosclerosis. Proprotein convertase subtilisin/kexin type...
Main Authors: | Yan Ma, Wei Li, Xue Wang, Liqun Jiao, Tao Wang, Bin Yang, Jichang Luo, Wenjing Li, Kan Liu, Ran Xu, Wanying Liao, Kaixun Huang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2022-11-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/12/11/e062046.full |
Similar Items
-
Effects of PCSK9 Targeting: Alleviating Oxidation, Inflammation, and Atherosclerosis
by: Emily Punch, et al.
Published: (2022-02-01) -
Interactions between PCSK9 and NLRP3 inflammasome signaling in atherosclerosis
by: Yanan Wang, et al.
Published: (2023-02-01) -
Impact of conventional lipid-lowering therapy on circulating levels of PCSK9: protocol for a systematic review and meta-analysis of randomised controlled trials
by: Yan Ma, et al.
Published: (2022-09-01) -
PCSK9 inhibitors
by: Baris Gencer, et al.
Published: (2015-04-01) -
Safety of PCSK9 inhibitors
by: Grzegorz Grześk, et al.
Published: (2022-12-01)